Linezolid Pharmacokinetics In Patients With Impaired Renal Function (PPT6)

Not Applicable

Completed

• Conditions: Renal Failure; Impaired Renal Function
• Interventions: Drug: 600 mg linezolid

• Registration Number: NCT02087566
• Lead Sponsor: Damanhour University

Brief Summary

Renal failure patients were treated with linezolid (LZD) for proven or suspected infections by multiresistant Gram-positive cocci. The aim of this study is to determine if dose adjustment of LZD is needed as a function of renal impairment or not, especially that a significant component of LZD is eliminated unchanged in urine.

Detailed Description

Not available

Study Timeline

• Study Start: 2013-10
• Primary Completion: 2014-01
• Study Completion: 2014-01
• Status Verified: 2014-03
• Study First Submitted: 2014-03-12
• Study First Submitted QC: 2014-03-13
• Last Update Submitted: 2014-03-13
• Study First Posted: 2014-03-14
• Last Update Posted: 2014-03-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 18

Inclusion Criteria

• Healthy subjects with normal renal function (CLcr ˃80 ml/min);
• Patients with acute renal failure (RF) (30˂CLcr˂80 ml/mine)
• Patients on long term HD with an ideal body weight of >60 kg and a body mass index between 20 and 26 kg/m2
• Passed all the screening parameters
• Free of any drug exposure known to interfere with the pharmacokinetics or assay of linezolid for at least 10 days prior to the study
• Able to communicate effectively with study personnel, be literate, and able to give consent.

Read More

Exclusion Criteria

Had a history of clinically significant organ dysfunction other than renal disease or those diseases associated with renal disease (as in case of acute RF or ESRD patients) Had physical examination or laboratory test results outside the inclusion such as; sitting systolic BP (SBP) of >140 or <100 mmHg, diastolic BP (DBP) > 90 or <60mm Hg (as in case of healthy volunteers and acute RF patients), or a pulse rate of > 95 or < 50 beats/min at screening; history of orthostatic hypotension; history of serious intolerance, allergy or sensitivity to linezolid ; history of blood dyscrasias; history of alcohol, smoking, or drug abuse; donation of blood during the 8 weeks prior to the study or plans to donate blood during or within 8 weeks of completing the study; unable to tolerate vein puncture and multiple blood samplings; any surgical/medical condition that might alter the absorption, distribution, metabolism, excretion of linezolid ; or can't follow instructions, according to the investigator's opinion.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Administration of linezolid to 6 healthy volunteers	600 mg linezolid	Administration of linezolid to 6 healthy volunteers {six healthy subjects with normal renal function (CLcr ˃80 ml/min)}
Administration of linezolid to 6 acute renal failure patients	600 mg linezolid	Administration of linezolid to 6 acute renal failure patients {(six patients with acute renal failure (RF) (30˂CLcr˂80 ml/mine)}
Administration of linezolid to 6 ESRD patients	600 mg linezolid	Administration of linezolid to 6 end-stage renal disease (ESRD) patients during an intra-dialytic period (on-dialysis): 6 patients on long term HD (minimum period of dialysis was 40 month while maximum period were 130 month) with an ideal body weight of \>60 kg (calculated as {height (cm) -100}×0.9) and a body mass index between 20 and 26 kg/m2 (calculated as {weight (kg)/height (m2)}).

Primary Outcome Measures

Name	Time	Method
Tolerability	Participants will be followed for the duration of study, an expected average of 6 weeks.	Tolerability was assessed based on changes in vital signs (temperature, blood pressure, pulse, and heart rate), measured before dosing in each period and approximately every 4 hours thereafter, and laboratory tests (hematology, biochemistry, liver function, and urinalysis), and performed at baseline and at the end of the study. In addition, a physician questioned volunteers about any adverse events occurring during the study, addressed them as necessary, and recorded them on the appropriate form. This physician was not blinded to treatment, but had no involvement in the study.